Mural Oncology plc [NASDAQ: MURA] plunged by -$0.01 during the normal trading session on Friday and reaching a high of $2.08 during the day while it closed the day at $2.06.
Mural Oncology plc stock has also loss -0.96% of its value over the past 7 days. However, MURA stock has declined by -21.37% in the 3 months of the year. Over the past six months meanwhile, it has lost -44.02% and lost -37.39% year-on date.
The market cap for MURA stock reached $35.69 million, with 17.27 million shares outstanding and 12.67 million shares in the current float. Compared to the average trading volume of 252.23K shares, MURA reached a trading volume of 166135 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Mural Oncology plc [MURA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MURA shares is $6.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MURA stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Raymond James have made an estimate for Mural Oncology plc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on March 25, 2025. The new note on the price target was released on March 25, 2025, representing the official price target for Mural Oncology plc stock. Previously, the target price had yet another raise to $15, while Rodman & Renshaw analysts kept a Buy rating on MURA stock.
The Price to Book ratio for the last quarter was 0.61, with the Price to Cash per share for the same quarter was set at 4.56.
MURA stock trade performance evaluation
Mural Oncology plc [MURA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.96. With this latest performance, MURA shares dropped by -8.44% in over the last four-week period, additionally sinking by -44.02% over the last 6 months – not to mention a drop of -36.02% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MURA stock in for the last two-week period is set at 51.03, with the RSI for the last a single of trading hit 0.07, and the three-weeks RSI is set at 0.10 for Mural Oncology plc [MURA]. The present Moving Average for the last 50 days of trading for this stock 2.22, while it was recorded at 2.06 for the last single week of trading, and 2.92 for the last 200 days.
Mural Oncology plc (MURA) Capital Structure & Debt Analysis
According to recent financial data for Mural Oncology plc. ( MURA), the Return on Equity (ROE) stands at -111.75%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -91.26%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Mural Oncology plc’s Return on Invested Capital (ROIC) is -249.63%, showcasing its effectiveness in deploying capital for earnings.
Mural Oncology plc (MURA) Efficiency & Liquidity Metrics
Based on Mural Oncology plc’s (MURA) latest financial statements, the Debt-to-Equity Ratio is 0.09%, indicating its reliance on debt financing relative to shareholder equity.
Mural Oncology plc (MURA) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Mural Oncology plc. (MURA) effectively leverages its workforce, generating an average of -$1268534.48 per employee. The company’s liquidity position is robust, with a Current Ratio of 2.87% and a Quick Ratio of 2.87%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Mural Oncology plc [MURA] stock
With the latest financial reports released by the company, Mural Oncology plc posted -1.87/share EPS, while the average EPS was predicted by analysts to be reported at -1.96/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.09. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MURA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Mural Oncology plc go to 74.89%.
Mural Oncology plc [MURA]: Institutional Ownership
There are presently around $47.23%, or 54.31%% of MURA stock, in the hands of institutional investors. The top three institutional holders of MURA stocks are: ARMISTICE CAPITAL, LLC with ownership of 1.69 million shares, which is approximately 9.9735%. SOLAS CAPITAL MANAGEMENT, LLC, holding 1.27 million shares of the stock with an approximate value of $$3.98 million in MURA stocks shares; and SOLAS CAPITAL MANAGEMENT, LLC, currently with $$2.63 million in MURA stock with ownership which is approximately 4.94%.
